Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 100-106

  Okamura, Kyoko ^a   Harada, Taishi ^a   Wang, Shuo ^a   Ijichi, Kayo ^a   Furuyama, Kazuto ^a   Koga, Takaomi ^a   Okamoto, Tatsuro ^a   Takayama, Koichi ^a   Yano, Tokujiro ^b   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

Author keywords

BDNF; Invasion; Lung cancer; Prognosis; Survival; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR;

AGED; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

AGED; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, TRKB;

EID: 84866181540     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.011     Document Type: Article

References (39)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003, 4:299-309.
3. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001, 169:107-114.
4. Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol 1994, 25:1386-1403.
5. Geiger T.R., Peeper D.S. The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 2005, 65:7033-7036.
6. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
7. Kupferman M.E., Jiffar T., El-Naggar A., Yilmaz T., Zhou G., Xie T., et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010, 29:2047-2059.
8. Huang Y.T., Lai P.C., Wu C.C., Hsu S.H., Cheng C.C., Lan Y.F., et al. BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells. Int J Oncol 2010, 36:1469-1476.
9. Asgharzadeh S., Pique-Regi R., Sposto R., Wang H., Yang Y., Shimada H., et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006, 98:1193-1203.
10. Nakagawara A., Azar C.G., Scavarda N.J., Brodeur G.M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994, 14:759-767.
11. Sclabas G.M., Fujioka S., Schmidt C., Li Z., Frederick W.A., Yang W., et al. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 2005, 11:440-449.
12. Eggert A., Grotzer M.A., Ikegaki N., Zhao H., Cnaan A., Brodeur G.M., et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 2001, 19:689-696.
13. Yu Y., Zhang S., Wang X., Yang Z., Ou G. Overexpression of TrkB promotes the progression of colon cancer. APMIS 2010, 118:188-195.
14. Patani N., Jiang W.G., Mokbel K. Brain-derived neurotrophic factor expression predicts adverse pathological and clinical outcomes in human breast cancer. Cancer Cell Int 2011, 11:23.
15. Tanaka K., Mohri Y., Nishioka J., Kobayashi M., Ohi M., Miki C., et al. Neurotrophic receptor, tropomyosin-related kinase B as an independent prognostic marker in gastric cancer patients. J Surg Oncol 2009, 99:307-310.
16. Zhang Y., Fujiwara Y., Doki Y., Takiguchi S., Yasuda T., Miyata H., et al. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Oncology 2008, 75:17-26.
17. Lam C.T., Yang Z.F., Lau C.K., Tam K.H., Fan S.T., Poon R.T. Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma. Clin Cancer Res 2011, 17:3123-3133.
18. Tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon. W.D. Travis, E. Brambilla, H.K. Mueller-Hermelink, C.C. Harris (Eds.).
19. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM classification of malignant tumours (UICC international union against cancer) 2009, John Wiley & Sons, Chichester. 7th ed.
20. Zhang S., Guo D., Luo W., Zhang Q., Zhang Y., Li C., et al. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer 2010, 10:43.
21. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
22. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
23. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
24. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
25. Thiele C.J., Li Z., McKee A.E. On Trk - the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009, 15:5962-5967.
26. Terry J., De Luca A., Leung S., Peacock G., Wang Y., Elliot W.M., et al. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes. Arch Pathol Lab Med 2011, 135:433-439.
27. Ricci A., Greco S., Mariotta S., Felici L., Bronzetti E., Cavazzana A., et al. Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 2001, 25:439-446.
28. Nakamura K., Martin K.C., Jackson J.K., Beppu K., Woo C.W., Thiele C.J. Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 2006, 66:4249-4255.
29. Au C.W., Siu M.K., Liao X., Wong E.S., Ngan H.Y., Tam K.F., et al. Tyrosine kinase B receptor and BDNF expression in ovarian cancers - effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 2009, 281:151-161.
30. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
31. Coudert B., Ciuleanu T., Park K., Wu Y.L., Giaccone G., Brugger W., et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012, 23:388-394.
32. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
33. Bang Y.J. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol 2011, 3:279-291.
34. Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26:626-632.
35. Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
36. Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
37. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
38. Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., Sciarrotta M., et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 2008, 29:609-616.
39. Harada T., Yatabe Y., Takeshita M., Koga T., Yano T., Wang Y., et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 2011, 17:2638-2645.